Biogen, Inc. (NASDAQ/BGEN) today announced that Peter N. Kellogg has been appointed Executive Vice President, Finance and Chief Financial Officer. Mr. Kellogg reports to James C. Mullen, President and Chief Executive Officer.

Mr. Kellogg joined Biogen in July 2000 as Vice President, Finance and Chief Financial Officer. From 1987-2000, he was associated with PepsiCo Inc. in a variety of senior financial and management capacities in both Frito-Lay International and PepsiCo. He was most recently Senior Vice President, PepsiCo E-Commerce and Senior Vice President and Chief Financial Officer, Frito-Lay International. Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Booz Allen & Hamilton and Arthur Andersen & Co.

In his position as Executive Vice President, Finance and Chief Financial Officer, Mr. Kellogg will lead the Global Accounting, Business Planning, Tax, Treasury, Investor Relations, and Strategic Sourcing functions.

Mr. Mullen said, “Peter Kellogg has made considerable contributions to Biogen since joining the company a year ago. He has helped us refine Biogen’s corporate direction and demonstrated excellent leadership across the organization. He plays a key strategic role on our senior management team and contributes insights and experience to our challenge of building Biogen into a global industry leader. He is also a superior manager and has added depth and sophistication to our expanding worldwide finance functions.”

Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from international sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at